Nuchal Translucency and the Risk of Congenital Heart Disease
- 1 February 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Obstetrics & Gynecology
- Vol. 109 (2, Part 1), 376-383
- https://doi.org/10.1097/01.aog.0000250473.99575.72
Abstract
To estimate whether nuchal translucency assessment is a useful screening tool for major congenital heart disease (CHD) in the absence of aneuploidy. Unselected patients with singleton pregnancies at 10(3/7) to 13(6/7) weeks of gestation were recruited at 15 U.S. centers to undergo nuchal translucency sonography. Screening characteristics of nuchal translucency in the detection of major CHD were determined using different cutoffs (2.0 or more multiples of the median [MoM], 2.5 or more MoM, 3.0 or more MoM). A total of 34,266 euploid fetuses with cardiac outcome data were available for analysis. There were 224 cases of CHD (incidence 6.5 per 1,000), of which 52 (23.2%) were major (incidence 1.5 per 1,000). The incidence of major CHD increased with increasing nuchal translucency: 14.1 per 1,000, 33.5 per 1,000, and 49.5 per 1,000 at 2.0 or more MoM, 2.5 or more MoM, and 3.0 or more MoM cutoffs, respectively. Sensitivity, specificity, and positive predictive values were 15.4%, 98.4%, and 1.4% at 2.0 or more MoM; 13.5%, 99.4%, and 3.3% at 2.5 or more MoM; and 9.6%, 99.7%, and 5.0% at 3.0 or more MoM. Nuchal translucency of 2.5 or more MoM (99th percentile) had a likelihood ratio (95% confidence interval) of 22.5 (11.4-45.5) for major CHD. Based on our data, for every 100 patients referred for fetal echocardiography with a nuchal translucency of 99th percentile or more, three will have a major cardiac anomaly. Nuchal translucency sonography in the first trimester lacks the characteristics of a good screening tool for major CHD in a large unselected population. However, nuchal translucency of 2.5 or more MoM (99th percentile or more) should be considered an indication for fetal echocardiography. II.Keywords
This publication has 24 references indexed in Scilit:
- First-Trimester or Second-Trimester Screening, or Both, for Down's SyndromeNew England Journal of Medicine, 2005
- First-Trimester Septated Cystic HygromaObstetrics & Gynecology, 2005
- Elevated first-trimester nuchal translucency increases the risk of congenital heart defectsAmerican Journal of Obstetrics and Gynecology, 2005
- Increased nuchal translucency and congenital heart defects in a low‐risk populationPrenatal Diagnosis, 2003
- Executive summaryJournal of Medical Screening, 2003
- The incidence of congenital heart diseaseJournal of the American College of Cardiology, 2002
- Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort studyBMJ, 1999
- Trends and Outcomes After Prenatal Diagnosis of Congenital Cardiac Malformations by Fetal Echocardiography in a Well Defined Birth Population, Atlanta, Georgia, 1990–1994Journal of the American College of Cardiology, 1996
- Fetal echocardiography: retrospective review of clinical experience and an evaluation of indicationsObstetrics & Gynecology, 1995
- Extended fetal echocardiographic examination for detecting cardiac malformations in low risk pregnancies.BMJ, 1992